The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

DKK 2016 | Personalised medicine in CLL: Redefining the treatment approach

Name: Personalised medicine in CLL: Redefining the treatment approach
Uploaded: 2016-02-25T00:00:00Z
Duration: 3 min 41 s
Description: At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from the University of Cologne, Cologne, Germany, discusses chemotherapy, kinase inhibitors and ongoing research in personalized approaches for the treatment of patients with chronic lymphocytic leukemia.

Michael Hallek • 25 Feb 2016

DKK 2016

Chronic Lymphocytic Leukemia Ibrutinib Idelalisib

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from the University of Cologne, Cologne, Germany, discusses chemotherapy, kinase inhibitors and ongoing research in personalized approaches for the treatment of patients with chronic lymphocytic leukemia.